Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease

NCT04445831 is registered in ClinicalTrials.gov with AC Immune SA as lead sponsor.

NCT NCT04445831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04445831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease
Lead sponsor
AC Immune SA
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2019
Completion date
September 5, 2023
Enrollment
57 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, brain diseases, central nervous system diseases, cognitive impairment, dementia, mild cognitive impairment, tauopathies